BioVie Inc. Warrant Share Price

BioVie Inc. Warrant Share Price

NASDAQ: BIVIW | Micro Cap
$0.28
-$0.02 (-6.67%) Last updated on 20 Oct, 2026 | 23:25 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

BioVie Inc. Warrant Stock Performance

Open
$0.28
Prev. Close
$0.30
Circuit Range
N/A
Day Range
$0.28 - $0.28
Year Range
$0.15 - $0.63
Volume
3,001
Average Traded
$0.28

BioVie Inc. Warrant Share Price Today

As of 30 October 2026, BioVie Inc. Warrant's share price is $0.28. The stock opened at $0.28, compared to its previous close of $0.30. During today's trading session, BioVie Inc. Warrant's share price traded between $0.28 and $0.28, with an average price of $0.28. Over the past 52 weeks, the stock has recorded a high of $0.63 and a low of $0.15. In terms of performance, BioVie Inc. Warrant's share price has declined by 13.31% over the last six months and is down 36.51% on a year-on-year basis.

BioVie Inc. Warrant Share Price Chart

$0.28$0.28
L
Show Current Price
H

BioVie Inc. Warrant Stock Fundamentals & Key Indicators

Market Cap
$413664.16
PE Ratio (TTM)
N/A
Dividend Yield
N/A
EPS (TTM)
N/A
Revenue (TTM)
$0.00
Return On Equity (TTM)
-215.34%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-10.14%

BioVie Inc. Warrant Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$5.13-$6.07-$5.27-$5.65
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-18.32%13.18%-7.21%

BioVie Inc. Warrant Annual Profit & Loss

All figures in USD

Particulars2026
Revenue$0.00
Net Profit-$22.12
Net Profit MarginN/A
Income ChangeN/A

About BioVie Inc. Warrant

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

BioVie Inc. Warrant Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$0.28
$0.28
-6.67%
Sep 2026
$0.31
$0.30
+9.89%
Aug 2026
$0.22
$0.27
+18.70%
Jun 2026
$0.23
$0.23
+34.50%
Apr 2026
$0.21
$0.17
-20.09%
Mar 2026
$0.26
$0.21
-33.75%
Jan 2026
$0.28
$0.32
+19.63%
Nov 2025
$0.21
$0.27
-22.41%
Oct 2025
$0.43
$0.35
-30.40%
Sep 2025
$0.38
$0.50
+13.38%
Aug 2025
$0.34
$0.44
N/A

BIVIW Share Price FAQs